Bal Pharma to close down parenterals & IV fluids facility at Pune

According to Section 25FFA of The Industrial Disputes Act, 1947, a company needs to give sixty days notice of its intention to close down the undertaking.

Bal Pharma Ltd, which is the largest producer of the bulk drug gliclazide (an anti-diabetic drug) in India, had established Pune unit in 1997. The finished dosage facility manufactures intravenous fluids, ophthalmic preparations & liquid oral preparations. In addition to exports, the plant also catered to the needs of companies for contract manufacturing, both in India and abroad. The Pune plant annual capacity of 18 million vials, 6 million IV bottles and 5 million syrups bottles.